<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi>, a DNA <z:chebi fb="36" ids="29309">methyl</z:chebi> transferase inhibitor, is effective in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Whether responses to <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> are achieved by demethylation of key genes or by cytotoxicity is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>Of 34 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) treated with <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi>, 7 achieved complete remissions (CR) (21%) and 6 achieved haematological improvement </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> six had less than 5% bone marrow (BM) blasts at the time of haematological improvements (HI) (2 had pre-existing refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), 4 had refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>)) </plain></SENT>
<SENT sid="4" pm="."><plain>A further patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> had blast reduction to less than 5% without HI </plain></SENT>
<SENT sid="5" pm="."><plain>Five of the seven (71%) complete responders had chromosome 7 abnormalities </plain></SENT>
<SENT sid="6" pm="."><plain>BM CR predicted longer overall survival (OS) (median 23 versus 9 months, P=0.015) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="17137">Bisulphite</z:chebi> genomic sequencing (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BGS</z:e>) of the CDKN2B (p15(INK4b)) promoter showed low level, <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> pretreatment methylation (mean 12.2%) in 14/17 (82%) patients analysed </plain></SENT>
<SENT sid="8" pm="."><plain>Lower baseline methylation occurred in responders (9.8% versus 16.2% in non-responders P=0.07) </plain></SENT>
<SENT sid="9" pm="."><plain>No response was seen in patients with &gt;24% methylation, in whom p15(INK4b) <z:chebi fb="2" ids="33699">mRNA</z:chebi> was not expressed </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> reduced CDKN2B methylation by mean 6.8% in 8/17 (47%) patients, but this did not correlate with response </plain></SENT>
<SENT sid="11" pm="."><plain>At 75 mg/m(2), cell <z:hpo ids='HP_0011420'>death</z:hpo> (reduced BM cellularity (P=0.001) and <z:mp ids='MP_0006042'>increased apoptosis</z:mp> (P=0.02)) rather than demethylation of CDKN2B correlates with response </plain></SENT>
<SENT sid="12" pm="."><plain>Patients with &gt;24% methylation may benefit from alternative dosing or combination strategies </plain></SENT>
</text></document>